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Risk of chronic kidney disease after cancer 
nephrectomy
Lin Li, Wei Ling Lau, Connie M. Rhee, Kevin Harley, Csaba P. Kovesdy, John J. Sim, Steve Jacobsen, 
Anthony Chang, Jaime Landman and Kamyar Kalantar-Zadeh
Abstract | The incidence of early stage renal cell carcinoma (RCC) is increasing and observational studies have 
shown equivalent oncological outcomes of partial versus radical nephrectomy for stage I tumours. Population 
studies suggest that compared with radical nephrectomy, partial nephrectomy is associated with decreased 
mortality and a lower rate of postoperative decline in kidney function. However, rates of chronic kidney disease 
(CKD) in patients who have undergone nephrectomy might be higher than in the general population. The risks of 
new-onset or accelerated CKD and worsened survival after nephrectomy might be linked, as kidney insufficiency 
is a risk factor for cardiovascular disease and mortality. Nephron-sparing approaches have, therefore, been 
proposed as the standard of care for patients with type 1a tumours and as a viable option for those with type 1b 
tumours. However, prospective data on the incidence of de novo and accelerated CKD after cancer nephrectomy 
is lacking, and the only randomized trial to date was closed prematurely. Intrinsic abnormalities in non-neoplastic 
kidney parenchyma and comorbid conditions (including diabetes mellitus and hypertension) might increase 
the risks of CKD and RCC. More research is needed to better understand the risk of CKD post-nephrectomy, to 
develop and validate predictive scores for risk-stratification, and to optimize patient management.
Li, L. et al. Nat. Rev. Nephrol. 10, 135–145 (2014); published online 14 January 2014; doi:10.1038/nrneph.2013.273
Introduction
Renal cell carcinoma (RCC) is the third most common 
genitourinary malignancy in the USA (after prostate and 
bladder cancers), and the seventh and the ninth leading 
cause of any cancer in men and in women, respectively.1 
In 2012, >64,000 people in the USA were diagnosed 
with cancer of the kidney—predominantly RCC—and 
approximately 13,000 associated deaths were reported.2 
The incidence of RCC has been increasing steadily 
for the past two decades, largely due to advancements 
in diagnostic technology and easier access to abdominal 
imaging for unrelated conditions. As a result, the size 
and the stage of tumours at the time of diagnosis has 
decreased.3 Incidental asymptomatic stage I tumours 
(type 1a [T1a] and type 1b [T1b], tumour diameters 
≤4 cm and ≤7cm, respectively) now account for more 
than half of newly diagnosed RCCs.4,5
Surgical resection remains the gold-standard treatment 
for RCC. Although very promising, alternative manage-
ment strategies, such as ablation and active surveillance, 
require longer term follow-up duration and are still under 
investigation. For decades radical nephrectomy was the 
primary treatment for kidney tumours regardless of 
their size,6 whereas partial nephrectomy was reserved 
for patients with imperative indications, such as a soli-
tary kidney, bilateral renal tumours, or pre-existing renal 
disease.7 However, the management of small localized 
renal tumours has evolved substantially over time, with 
an increasing emphasis on preservation of renal volume 
and function. In the past decade, several studies have dem-
onstrated oncological equivalence of partial nephrectomy 
compared with radical nephrectomy for stage I lesions.8–12 
Although 5-year cancer-specific survival is >90%, regard-
less of surgical approach,13,14 emerging evidence favours 
partial nephrectomy over radical nephrectomy because 
the less-invasive surgery is associated with a lower inci-
dence of postoperative chronic kidney disease (CKD) 
and a reduction in associated adverse cardiovascular 
outcomes. Partial nephrectomy has, therefore, become 
the preferred nephron-sparing surgery in elective set-
tings and is now offered to patients with unilateral small 
renal masses and normal contralateral kidney function. 
In 2009, the American Urological Association published 
clinical guidelines that suggested partial nephrectomy as 
the standard of care for T1a RCC and as a viable option 
for T1b RCC.15 Similar guidelines were later endorsed by 
the European Association of Urology.16
In this Review, we describe the available evidence and 
ongoing controversy regarding the potential benefits 
of partial versus radical nephrectomy for small renal 
masses, in particular T1a lesions. We also discuss the risk 
of de novo kidney disease or acceleration of CKD pro-
gression post-nephrectomy, potential factors that might 
influence patient prognosis after this surgery, and the 
need for further research to better understand the natural 
history and progression of CKD after nephrectomy.
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Nephrectomy and CKD
CKD is now recognized as a public health problem 
worldwide. The disease is defined as kidney damage for 
>3 months (confirmed by pathologic abnormalities in 
biopsy samples or by markers of kidney damage such 
as proteinuria) with or without changes in glomerular 
filtration rate (GFR), or GFR <60 ml/min/1.73 m2 for 
>3 months with or without kidney damage.17 The inci-
dence and prevalence of CKD have been steadily increas-
ing worldwide, both in developed countries and in large 
emerging economies, such as India and China.18 The 
Center for Disease Control and Prevention estimated 
that >10% of the US population—or >20 million people 
aged ≥20 years in the USA—had CKD in 2010.19
Radical nephrectomy for RCC was first described in 
1969.6 The procedure (as originally described) involves 
complete resection of the kidney, adrenal gland, and 
tumour within the Gerota’s fascia as well as local lym-
phadenectomy and results in excellent local tumour 
control.6 In the past, urologists advised their patients 
that the impact of radical nephrectomy on kidney func-
tion was minimal, based on data extrapolated from 
several large cohort studies of kidney donors. These 
studies showed that after unilateral radical nephrec-
tomy for transplant donation, normal renal function 
could be maintained by a solitary kidney at long-term 
follow up.20–22 Radical nephrectomy was, therefore, con-
sidered the standard of care for localized renal masses. 
However, the typical transplant donor population differs 
significantly from patients with RCC, who tend to be 
much older than healthy screened kidney donors, and 
often have pre-existing kidney diseases and risk factors 
(such as diabetes mellitus, hypertension, smoking, and 
obesity) that might predispose them towards developing 
both kidney tumours and kidney damage.23,24
Single-centre retrospective studies
Evidence that radical nephrectomy, compared with 
partial nephrectomy, for the treatment of small local-
ized renal masses could lead to a substantial decline in 
kidney function emerged in the mid-1990s (Tables 1 
and 2). Butler et al.25 were among the first to report 
an adverse effect of radical nephrectomy on estimated 
glomerular filtration rate (eGFR). They found that 
patients with RCC who underwent radical nephrec-
tomy had significantly higher postoperative mean serum 
creatinine levels than those who underwent partial 
nephrectomy. However, the study was limited by a small 
sample size (n = 88).
Data from larger single-centre retrospective studies 
of patients who underwent partial or radical nephrec-
tomy for T1a RCC were reported subsequently. In 
2000, a cohort study of patients with unilateral RCC 
and a normal contralateral kidney who underwent 
either partial (n = 164) or radical nephrectomy (n = 164) 
between 1966 and 1969 was published. Patients were 
case-matched for pathology, tumour size, age, sex, and 
year of surgery. At 10-year follow-up, those who under-
went radical nephrectomy had a significantly higher 
estimated cumulative incidence of renal insufficiency 
(defined as serum creatinine level >176.8 μmol/l) than 
those who underwent partial nephrectomy (22.4% versus 
11.6%, hazard ratio [HR] 3.7, 95% CI 1.2–11.2).14 A study 
that included 290 patients from the Memorial Sloan–
Kettering Cancer Center (MSKCC), New York, USA, 
with a median follow-up of 25 months reported similar 
findings. At baseline the radical and partial nephrectomy 
groups had similar mean preoperative serum creatin-
ine levels (88.4 μmol/l and 86.63 μmol/l, respectively) 
and were comparable in terms of risk factors for renal 
insufficiency, including diabetes mellitus, hyper tension, 
age, American Society of Anaesthesiologists score for 
physical status,26 and smoking status. At the end of the 
follow-up period, the mean postoperative serum creatin-
ine level was significantly higher in the radical nephrec-
tomy group than in the partial nephrectomy group 
(132.6 μmol/l versus 88.4 μmol/l, P <0.001).27
Serum creatinine level alone is not a good index of 
renal function because of high day-to-day variability and 
inaccuracy at extremes of age and body habitus, such as 
obesity and amputation.28 However, the protective effect 
of nephron-sparing surgery on long-term renal func-
tion has been further confirmed by studies that used 
estimated GFR (eGFR) as a measure of renal function. 
In a retrospective cohort of 662 patients from MSKCC 
with normal baseline serum creatinine levels who under-
went elective partial or radical nephrectomy for a solitary 
T1a RCC between 1989 and 2005, 26% of participants 
had CKD defined as eGFR <60 ml/min/1.73 m2 (esti-
mated using the abbreviated Modification of Diet in 
Renal Disease equation29) before surgery.30 The impact 
of partial versus radical nephrectomy on the risk of CKD 
was examined using two different definitions of the 
disease: eGFR <60 ml/min/1.73 m2 or eGFR <45 ml/
min/1.73 m2. The 3-year postoperative probability of 
freedom from new onset of eGFR <60 ml/min/1.73 m2 
was 80% after partial nephrectomy versus 35% after 
radical nephrectomy (P <0.0001). Furthermore, prob-
ability for eGFR <45 ml/min/1.73 m2 was 95% after 
partial nephrectomy versus 64% after radical nephrec-
tomy (P <0.0001). Multivariable analysis showed that 
radical nephrectomy was an independent risk factor for 
the development of new onset CKD (HR 3.82, 95% CI 
Key points
 ■ Partial nephrectomy preserves renal function in the long term and is currently 
the preferred standard of care for small renal cell carcinomas (RCCs)
 ■ Evidence for a beneficial effect of nephron-sparing approaches versus radical 
nephrectomy for RCC on long-term chronic kidney disease (CKD)-associated 
morbidity and overall survival is inconclusive and controversial
 ■ The quantity and integrity of the preserved renal parenchyma after nephrectomy 
are important predictors of long-term renal outcomes
 ■ Renal tumours and CKD share intrinsic kidney risk factors and systemic 
comorbidities and a bi-directional relationship between RCC and CKD has 
been proposed
 ■ Further research is needed to quantify the perioperative risks and potential 
long-term benefits of nephron-sparing surgery for RCC
 ■ A prediction model to identify patients at risk of oncological and nononcological 
morbidity and mortality after nephrectomy would help personalize the 
management of patients with small RCCs
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2.75–5.32 for eGFR <60 ml/min/1.73m2; and HR 11.8, 
95% CI 6.24–22.4 for eGFR <45 ml/min/1.73 m2).30 
The finding that partial nephrectomy was associ-
ated with improved long-term renal function compared 
with radical nephrectomy has been validated in several 
 subsequent analyses.31–33
Population-based studies
Several retrospective population-based analyses have 
been carried out to further examine renal outcomes 
after nephrectomy. In a study of 1,151 patients who 
underwent radical or partial nephrectomy in Alberta, 
Canada, in 2002–2007, 10.5% of participants had adverse 
renal outcomes, including end-stage renal disease 
(ESRD), urgent dialysis, CKD (defined as eGFR <30 ml/
min/1.73 m2), or rapidly progressive CKD (defined 
as eGFR <60 ml/min/1.73 m2 with a decline in eGFR 
≥4 ml/min/1.73 m2 per year) during a mean follow-up 
duration of 32 months.34 In addition, radical nephrec-
tomy nearly doubled the risk of adverse renal outcomes 
when compared with partial nephrectomy (HR 1.75, 
95% CI 1.02–2.99).
A study that included all patients (n = 44) who 
underwent partial nephrectomy for RCC in Iceland in 
2000–2010 reported similar findings.35 These patients 
were matched to participants who underwent radical 
nephrectomy according to time of operation, tumour 
node meta stasis stage, and tumour size. In compari-
son to partial nephrectomy, radical nephrectomy had 
a detrimental effect on eGFR 6 months after surgery 
(difference in eGFR of 12.6 ml/min/1.73 m2, P <0.001) 
and also increased the risk of new-onset CKD (defined 
as eGFR <60 ml/min/1.73 m2; OR 3.07, 95% CI 
1.03–9.79, P = 0.04).35
In a study of 6,433 patients who underwent partial or 
radical nephrectomy for T1a RCC in the USA between 
1998 and 2005, 840 patients from each group were care-
fully matched on propensity scores to account for selec-
tion biases.36 Those who underwent radical nephrectomy 
had a higher rate of new onset CKD than did those who 
underwent partial nephrectomy (20% versus 11%, HR 
1.90, 95% CI 1.48–2.45), and the 5-year freedom from 
new-onset CKD was estimated to be 82% for radical 
nephrectomy versus 91% for partial nephrectomy 
(P <0.001).36 These population-based studies confirm 
the protective effect of nephron-sparing surgery versus 
radical nephrectomy on renal outcomes in patients with 
T1a RCC.
Given the equivalent oncological outcomes of partial 
and radical nephrectomy,8–12 the compelling evidence 
Table 1 | Single-centre studies examining outcomes following partial versus radical nephrectomy
Study  
[population]
n Results Limitations
PN RN
Butler et al. (1995)25 
[Cleveland Clinic registry 
1975–1992, T1a tumours]
46 42 Similar cancer-specific 5-year survival in PN (100%) 
and RN (97%) groups
Significant increase in mean SCr levels after 
surgery in RN group only
Single-centre, retrospective study
Lau et al. (2000)14 
[Mayo Clinic registry 
1996–1999]
164 164 Similar overall survival and cancer-specific survival 
in RN and PN groups RN associated with increased 
risk of proteinuria and new-onset CKD* (RR 3.7)
Single-centre, retrospective study
McKiernan et al. (2002)27 
[MSKCC renal cancer 
database 1989–2000, 
T1a tumours]
117 173 RN associated with increased risk of development 
of CKD* (P <0.01)
Similar oncological outcomes in RN and PN groups
Single-centre, retrospective study
Small number of events 
prevented multivariate analysis 
(16 patients developed CKD in 
RN group)
Huang et al. (2006)30 
[MSKCC renal cancer 
database 1989–2005, 
T1a tumours, normal 
baseline SCr]
385 262 26% of patients had eGFR <60 ml/min/1.73 m2 and 
2% had eGFR <45 ml/min/1.73 m2‡ at baseline
In the multivariable analysis, RN was an 
independent risk factor for new-onset eGFR 
<60 ml/min/1.73 m2 at 3 years after surgery
Single-centre, retrospective study
Thompson et al. (2008)43 
[Mayo Clinic nephrectomy 
registry 1989–2003, 
isolated T1a renal cortical 
tumours]
358 290 No significant association between RN versus PN 
and death (RR 1.12, 95% CI 0.80–1.56)
In patients aged >65 years (n = 327), RN 
associated with increased risk of death (RR 2.16, 
95% CI 1.12–4.19), which persisted after 
adjustment for SCr levels at baseline
Single-centre, retrospective study
Small subset of patients aged 
<65 years with low rate of events 
(43 deaths)
Barlow et al. (2010)31 
[Columbia Comprehensive 
Clinical Database of Urologic 
Oncology 1988–2008]
102 174 Pre-operative CKD stage and RN were 
independent predictors of worse renal outcomes‡
Single-centre, retrospective study
Yokoyama et al. (2011)32 
[Tokyo Medical and Dental 
University Graduate School 
1994–2009]
75 341 4% prevalence of preoperative CKD RN was an 
independent risk factor for new-onset CKD (eGFR 
<60 ml/min/1.73 m2;‡ 37% in RN group versus 
11% in PN group)
Single-centre, retrospective study
*SCr level >152.50 μmol/l. ‡Modification in Diet and Renal Disease Study equation. Abbreviations: eGFR, estimated glomerular filtration rate; MSKCC, Memorial 
Sloan–Kettering Cancer Center; PN, partial nephrectomy; RN, radical nephrectomy; RR, relative risk; SCr, serum creatinine.
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described above supports the current recommendation 
that partial nephrectomy should be the standard of care for 
T1a RCC, and a viable option for T1b RCC.15,16 This strat-
egy might preserve renal function and avoid the potential 
sequelae associated with development of CKD.
Nephrectomy and cardiovascular outcomes
More than half of RCCs are discovered in the early stages 
by incidental abdominal imaging37 and the majority of 
patients with stage I RCC are expected to remain free 
of recurrence and metastasis for >5 years after surgical 
Table 2 | Population-based studies and randomized controlled trial examining outcomes after partial versus radical nephrectomy
Study [population] n Results Limitations
PN RN
Population-based studies
Miller et al. (2008)50 [SEER 
registry data linked with Medicare 
claims 1991–2002]
763 10,123 PN associated with fewer adverse renal outcomes
No difference in cardiovascular outcomes
In 2000–2002, PN associated with reduced overall 
mortality (HR 0.72, 95% CI 0.56–0.92)
Retrospective study
All patients aged >65 years
Huang et al. (2009)44 [SEER 
registry data linked with Medicare 
claims 1995–2002 T1a tumours]
556 2,547 RN associated with increased overall mortality (HR 
1.38, P <0.01) and number of post-operative 
cardiovascular events (HR 1.4, P <0.05), but not with 
cardiovascular death (HR 0.95, P = 0.84)
Retrospective study
All patients aged >65 years
No data on perioperative kidney function and 
comorbidities
Zini et al. (2009)45 [Nine SEER 
registries 1988–2004, 
T1a tumours]
2,198 7,611 RN associated with increased overall mortality (HR 1.23, 
P = 0.001) and non-cancer-related mortality at 10-year 
follow-up (31.6% in RN group versus 27.1% in PN group)
Retrospective study
No data on perioperative kidney function 
and comorbidities
Klarenbach et al. (2011)34 
[Alberta Kidney Disease Network 
data set 2002–2007]
230 921 RN associated with increased risk of adverse renal 
outcomes (HR 1.75, 95% CI 1.02–2.99)
Baseline proteinuria a strong risk factor for adverse 
renal outcomes (HR 2.4, 95% CI 1.47–3.88)
No information on tumour stage
Sun et al. (2012)36 [SEER registry 
data linked with Medicare claims 
1998–2005, T1a tumours]
840 840 In multivariable analysis, RN associated with higher rate 
of post-operative CKD (HR 1.9, 95% CI 1.48–2.45) and 
acute kidney injury (HR 1.41, 95% CI 1.12–1.79)
No significant difference in risk of end-stage renal 
disease (HR 1.76, 95% CI 0.97–3.19)
Retrospective study
All patients aged >65 years
Pre-operative kidney function not reported
Tan et al. (2012)47 [SEER registry 
data linked with Medicare claims 
1992–2007, T1a tumours, 
patients matched using 
propensity scores]
1,925 5,213 PN associated with lower risk of death (HR 0.54, 95% 
CI 0.34–0.85)
Patients living close to a PN surgeon were more likely 
to receive PN, but differential distance did not 
influence overall mortality
Retrospective study
All patients aged >65 years
Smaldone et al. (2012)51 [SEER 
registry data linked with Medicare 
claims 1995–2007, T1a tumours]
1,665 3,831 In patients aged 68–85 years, PN associated with 
survival benefit at 1 year and at 3 years post-surgery
Survival benefit of PN decreased with time (little benefit 
observed at 5 years and at 10 years after surgery)
Retrospective study
All patients aged >65 years
Data not adjusted for comorbidities
Kim et al. (2012)52 [Meta-analysis 
of 36 studies published in English 
between 1990 and 2011]
9,281 31,729 PN correlated with a 19% reduction in risk of all-cause 
mortality (HR 0.81, P <0.0001), a 29% reduction in 
cancer-specific mortality (HR 0.71, P <0.001), and a 61% 
reduction in risk of severe CKD (HR 0.39, P <0.0001)
Included 35 retrospective studies and only 
one randomized clinical trial
Substantial study heterogeneity
Mariusdottir et al. (2013)35 
[Icelandic Cancer Registry 
2000–2010, patients in PN and 
RN groups matched 1:1 according 
to time of operation, tumour node 
metastasis stage, and tumour size]
44 44 RN associated with a higher mean reduction in eGFR 
and an increased risk of new-onset CKD 6 months 
after surgery (eGFR <60 ml/min/1.73 m2*, OR 3.07, 
95% CI 1.03–9.79)
RN associated with higher mortality (5-year overall 
survival 65% in RN group versus 100% in PN group)
Retrospective study 
Shuch et al. (2013)46 [SEER 
registry data linked with Medicare 
claims 1992–2007 T1a tumours]
1,471 4,299 PN associated with higher overall survival (median of 
10.45 years) compared with matched controls 
(medians of 8.75 years for bladder cancer controls 
and 8.76 years for noncancer controls, P <0.001)
No survival benefits observed for RN
Retrospective study
All patients aged >66 years 
Randomized prospective clinical trial
Van Poppel et al. (2011)53 
[EORTC-GU multinational, 
noninferiority phase 3 trial 
1992–2003, isolated tumours 
<5 cm diameter]
268 273 In the intention-to-treat analysis, PN associated with 
an increased risk of mortality (HR 1.5, 95% CI 
1.03–2.16) and a slightly higher rate of cardiovascular 
deaths (9.3% versus 7.3% in the RN group)
No significant differences in mortality after PN or RN 
in patients with localized renal cell carcinomas <5 cm 
(n = 195 per group)
Study closed prematurely due to poor accrual
No hard conclusions because of small 
number of events and high crossover rate
Kidney function outcomes not assessed
Tumour size limit <5 cm instead of <4 cm 
(based on data available at time of study 
design)
*Modification in Diet and Renal Disease Study equation. Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; EORTC-GU, European Organization for Research 
and Treatment of Cancer Genito-Urinary Group; HR, hazard ratio; PN, partial nephrectomy; RN, radical nephrectomy; SEER, Surveillance, Epidemiology and End Results; SCr, serum creatinine.
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resection.13,14 Radical nephrectomy might control the 
tumour, but also increases the risk of CKD after surgery. 
The longer the patient is free of cancer, the higher their 
risk of developing CKD and its associated adverse 
 outcomes, particularly cardiovascular disease.
The adverse impact of declining renal function on 
cardiovascular events was illustrated by researchers who 
estimated longitudinal eGFR in >1 million patients in the 
USA with advanced CKD who progressed to dialysis or 
kidney transplantation between 1996 and 2000.38 This 
retrospective cohort study, which had a median follow-
up duration of ~3 years, was one of the first to demon-
strate that risk of cardiovascular events increased with a 
decline in eGFR. Patients with CKD and eGFR <60 ml/
min/1.73 m2 had higher risks of cardiovascular events (HR 
1.4, 95% CI 1.4–1.5) and of all-cause death (HR 1.2, 95% 
CI 1.1–1.2) than individuals with normal renal function. 
These risks were even higher in patients whose eGFR 
declined to <30 ml/min/1.73 m2 (HR 2.8, 95% CI 2.6–2.9 
and HR 3.2, 95% CI 3.1–3.4 for cardiovascular events and 
all-cause death, respectively).38 On the basis of these data 
and additional evidence, CKD is now deemed to be an 
independent risk factor for cardiovascular disease.39–41
Retrospective studies
As CKD is a risk factor for cardiovascular disease, the 
benefits of nephron-sparing surgery might extend beyond 
preservation of renal function. Systemic morbidities 
downstream of CKD after nephrectomy might lead to less-
favourable survival outcomes.42 However, the evidence for 
this association remains inconclusive and controversial, 
and the potential causal association between nephrec-
tomy and long-term CKD-associated morbidity and mor-
tality is uncertain. In a single-centre cohort of 648 patients 
who had unilateral, solitary, localized renal masses ≥4 cm 
and normal renal function at baseline, radical nephrectomy 
was associated with a significantly higher overall mortal-
ity than was partial nephrectomy (relative risk [RR] 2.16, 
P = 0.02) in patients <65 years of age.43 However, the differ-
ence in mortality between the two patient groups was not 
significant for the entire cohort, highlighting the hetero-
geneity of the long-term impact of this type of surgery and 
its interaction with age at the time of operation.43
Using data from the Surveillance, Epidemiology and 
End Results (SEER) cancer registry linked with Medicare 
claims, the outcomes in 2,991 patients aged ≥65 years of 
age who underwent radical or partial nephrectomy for T1a 
RCC between 1995 and 2002 have been ana lysed.44 After 
adjusting for preoperative demographic and  comorbid 
variables, radical nephrectomy was associated with an 
increased risk of overall mortality compared with partial 
nephrectomy (HR 1.38, P <0.01). Radical nephrectomy 
was also associated with increased risks of cardiovascular 
events (probabilities of freedom of 86% at 3 years and 82% 
at 5 years in the partial nephrectomy group, compared with 
82% at 3 years and 75% at 3 years in the radical nephrec-
tomy group), and cardio vascular death (4.9% in the partial 
nephrectomy group versus 6.0% in the radical nephrec-
tomy group). However, no significant difference was 
observed in time to cardio vascular event. Similarly, a study 
of 1988–2004 SEER registry data from 9,809 patients with 
T1a RCC showed that radical nephrectomy compared 
with partial nephrectomy, was associated with significantly 
increased overall mortality and non-cancer-related mor-
tality at median follow-ups of 35 months and 46 months, 
respectively.45 Radical nephrectomy resulted in an esti-
mated absolute increase in non-cancer-related  mortality 
of 4.6% at 5 years and 4.5% at 10 years after surgery.45
Statistical adjustment approaches
In an attempt to overcome the potential selection bias 
and confounding inherent to observational study designs, 
several SEER–Medicare linked cohorts of patients with 
T1a RCC have been re-examined using various statisti-
cal adjustment approaches. One such study used a greedy 
algorithm to match patients with localized RCC with 
control individuals (either without cancer or with non-
muscle-invasive bladder cancer) based on demographics 
and comorbidities.46 Median overall survival was longer 
in the partial nephrectomy group (10.45 years) than in 
matched control groups (8.75 years in the bladder cancer 
group and 8.76 years in the non-cancer group, P <0.001). 
However, these survival benefits were not observed for 
radical nephrectomy.46 A study that used differential 
distance between the patient’s residence and a partial 
nephrectomy physician as an instrumental variable (one 
of the most rigorous statistical methods used to date) 
reported that partial nephrectomy was associated with a 
significantly lower risk of overall mortality than radical 
nephrectomy (HR 0.54, 95% CI 0.34–0.85) and was not 
inferior in terms of kidney cancer-specific survival (HR 
0.82, 95% CI 0.19–3.49).47
Propensity score adjustment has also been increasingly 
used by several groups of investigators. A propensity score 
estimates the probability of receiving either radical or 
partial nephrectomy, conditional on known and meas-
urable demographic and disease-specific characteristics, 
to limit the influence of selection bias and confounding 
on treatment outcomes.48,49 In a subgroup analysis of 
2000–2002 data (4,422 and 438 patients with radical and 
partial nephrectomy, respectively, in the USA), partial 
nephrectomy was associated with a reduced risk of death 
from any cause (adjusted HR 0.72, 95% CI 0.56–0.92), but 
no association was observed between surgery type and 
postoperative cardiovascular morbidity.50
The reported survival benefit associated with partial 
nephrectomy was challenged by a study of patients older 
than 66 years with T1a RCC who underwent either partial 
(n = 1,665) or radical nephrectomy (n = 3,831) from 1995–
2007.51 After adjustment using propensity-score-based 
weighting, a survival benefit of partial versus radical 
nephrectomy was observed at 1 year and at 3 years after 
surgery. However, this survival benefit decreased with 
time and little survival benefit of partial versus radical 
nephrectomy was observed >5 years after surgery.51
Meta-analysis
A meta-analysis, which included 39 studies and 41,010 
patients who underwent nephrectomy for localized renal 
tumours (77% radical nephrectomy and 23% partial 
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nephrectomy), showed that partial versus radical nephrec-
tomy resulted in a 19% reduction in risk of all-cause mor-
tality (HR 0.81, P <0.0001). However, the investigators 
acknowledge that their analysis was limited by substan-
tial heterogeneity in study populations and the use of 
 historical cohorts in the majority of the included studies.52
EORTC trial
The debate regarding long-term non-oncological mor-
bidity and mortality after nephrectomy for small renal 
tumours was fuelled by the controversial European 
Organisation for Research and Treatment of Cancer 
(EORTC) trial53—the only randomized clinical trial of 
partial versus radical nephrectomy conducted to date. 
In this study, 541 patients who had solitary renal lesions 
with a diameter ≤5 cm and a normal contralateral kidney 
were randomly assigned to receive either partial or 
radical nephrectomy. Unfortunately, the trial was closed 
prematurely because of poor accrual and was limited by 
high crossover between the treatment groups.
In contrast to observational data, results from the 
EORTC trial showed more-favourable outcomes in 
patients treated with radical nephrectomy than in those 
who underwent partial nephrectomy.53 During a median 
follow-up of 9.3 years, 25% of patients who underwent 
partial nephrectomy and 18.3% of those who under-
went radical nephrectomy died. The leading cause of death 
was cardiovascular disease. The intention-to-treat analysis 
showed improved outcomes in the radical nephrectomy 
group with a 10-year overall survival rate of 81.1% com-
pared with 75.5% in the partial nephrectomy group (HR 
1.5, 95% CI 1.03–2.16). Interestingly, a subgroup analy-
sis of the EORTC trial showed that partial nephrectomy 
compared with radical nephrectomy was associated with 
a 21% reduction in the absolute risk of moderate renal 
dysfunction (eGFR <60 ml/min/1.73 m2) during a median 
follow-up of 6.7 years (absolute risk of 64.7% versus 
85.7%, 95% CI 13.8–28.3).54 The outcome of advanced 
CKD (eGFR <30 ml/min/1.73 m2) was reached by 10.0% 
of patients who underwent radical nephrectomy and 
6.3% of patients who underwent partial nephrectomy 
( difference of 3.7%, 95% CI –1.0 to 8.5).
The finding that partial nephrectomy compared with 
radical nephrectomy is associated with an increase in 
mortality, but a decrease in risk of CKD, suggests that 
moderate renal dysfunction arising from surgery might 
not have the same negative impact on overall mortality 
as does CKD arising from medical causes, such as dia-
betes or hypertension. Similar conclusions were reached 
by the authors of a retrospective study that included 4,180 
US patients who underwent nephrectomy for suspected 
cancer between 1999 and 2008. Before surgery, 28% of 
these patients had CKD (GFR <60 ml/min/1.73 m2) 
attributed to medical causes, whereas 22% of patients 
had CKD only after surgery.55 Surgically induced CKD 
and postoperative GFR were not significant predictors 
of overall survival in those patients who did not have 
CKD before surgery. The EORTC trial is largely con-
sidered to be flawed because of the accrual difficulties, 
pre mature closure, and high crossover between the treat-
ment groups. Nevertheless, as the likelihood of additional 
large prospective clinical studies of partial versus radical 
nephrectomy is low, this randomized trial is valuable 
and highlights the complexity and tremendous chal-
lenges faced when attempting to elucidate the potential 
relative long-term morbidity and mortality benefits of 
partial nephrectomy.
Risk factors for CKD after nephrectomy
The same intrinsic kidney risk factors and systemic 
comorbidities might predispose patients toward devel-
oping renal tumours and CKD.23,24 These factors include 
baseline demographics (such as age, gender and ethni-
city), environmental factors and habits (such as nutrition, 
smoking status and lifestyle), genetic factors (such as 
APOL1 variants), comorbid conditions (such as metabolic 
syndrome, diabetes mellitus, hypertension, and other 
acute or chronic disease states) and pre- existing abnor-
malities in the non-neoplastic kidney parenchyma. In the 
MSKCC study, 26% of patients with RCC had CKD and 
eGFR <60 ml/min/1.73 m2 before surgery despite normal 
preoperative serum creatinine levels.30 Hyperfiltration 
injury to the remaining glomeruli after partial or radical 
nephrectomy might further predispose patients with RCC 
to adverse long-term renal outcomes. The subsequent 
decline in kidney function might be more pronounced 
if subclinical intrinsic renal abnormalities were present 
before nephrectomy.34 Furthermore, lifestyle, demo-
graphic, and genetic factors as well as comorbid condi-
tions might have a role in increasing the risk of CKD, or 
accelerating the rate of progression of pre-existing CKD, 
after partial or total nephrectomy (Figure 1, Table 3).
Renal parenchymal abnormalities
Pathologic studies have established that glomerular 
disease or arterionephrosclerosis frequently coexist 
with RCC.56–58 Researchers that evaluated non- neoplastic 
renal parenchyma in resected tumour specimens 
reported that only 10% of 110 consecutive tumour 
nephrectomy specimens had completely normal adjacent 
renal tissue. Clinically significant intrinsic renal abnor-
malities, including diabetic nephropathy, glomerular 
Ischaemic
injury
Pre-existing
CKD
ESRD
Progression
of CKD
Vascular
injury
De novo
CKD
Risk
factors and
comorbidities
Nephron lossNephrectomy
Figure 1 | Potential pathophysiology of de novo CKD and progression of pre-existing 
CKD after kidney tumour nephrectomy. Vascular and ischaemic injury resulting from 
nephrectomy can lead to nephron loss, which, in combination with risk factors and 
comorbidities, might result in de novo CKD or progression of pre-existing CKD. 
Abbreviations: CKD, chronic kidney disease; ESRD, end-stage renal disease.
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hyper trophy, mesangial expansion, and diffuse glo-
merulosclerosis were evident in >60% of the remain-
ing samples.56 These findings prompted the College of 
American Pathologists to update the protocol for exam-
ination of tumour nephrectomy and nephroureterec-
tomy specimens, effective since January 2010, to require 
routine evaluation of non-neoplastic renal parenchyma.59
In a study of 110 consecutive tumour nephrectomy 
specimens, patients with clinically significant renal 
parenchymal abnormalities showed a greater decline 
in serum creatinine levels at 6-month follow-up than 
those who had normal tissue adjacent to their tumour 
(97.24 ± 159.12 μmol/l versus 17.68 ± 17.68 μmol/l, 
P = 0.01).56 However, the study was limited by the small 
number of available follow-up serum creatinine measure-
ments. Among 156 patients who were followed-up for a 
minimum of 12 months after tumour nephrectomy, the 
presence of severe arteriosclerosis or arteriolo sclerosis, 
>10% interstitial fibrosis or tubular atrophy, or >5% 
glomerulosclerosis in nephrectomy specimens were 
risk factors for significantly higher postoperative serum 
creatinine levels.58 Furthermore, elevation of postopera-
tive serum creatinine was much higher following radical 
nephrectomy than following partial nephrectomy given the 
same degree of these pre-existing parenchymal pathologic 
changes. Using eGFR, several other studies have reported 
similar associations between renal function outcomes 
and underlying histopathologic abnormalities evident in 
non-neoplastic renal parenchyma. In a study that included 
150 patients with a median follow-up of 15 months, the 
presence of arteriosclerosis was an independent predic-
tor of the percentage decline in eGFR after laparo scopic 
partial nephrectomy.60 By contrast, a study with longer 
follow-up duration (mean 19.7 months) showed that 
percentage change in eGFR after laparoscopic radical 
nephrectomy was significantly associated with the extent 
of glomerulo sclerosis (P = 0.034) but not with the extent of 
 arteriosclerosis or the presence of interstitial fibrosis.61 
For each 10% increase in  glomerulosclerosis, eGFR after 
surgery decreased by 9% from baseline.
Comorbidities
Pre-existing comorbidities might also compromise renal 
function after nephrectomy as a result of their long-term 
effects on the remnant renal parenchyma. Unsurprisingly, 
age, diabetes, hypertension, and tobacco use are indepen-
dently associated with the development of CKD after 
nephrectomy for RCC, as well as with renal insufficiency 
(defined as elevated serum creatinine levels or reduced 
eGFR before surgery) in the general population.31,33,34,62,63 
Significantly higher rates of proteinuria, which confers 
an additional risk of CKD or cardiovascular disease, have 
also been reported in patients who have undergone radical 
nephrectomy compared with those who have undergone 
partial nephrectomy.14,34,63,64
Preserved renal function
Preservation of renal parenchyma by partial nephrectomy 
is the most-likely mechanism for its observed advantage 
over radical nephrectomy in preventing CKD in patients 
with small renal tumours. Larger preserved renal volume, 
or functional volume, is an independent predictor of 
better renal function outcome among patients with a 
solitary kidney who have undergone partial nephrec-
tomy.65–67 A 5% increase in the amount of preserved 
kidney has been estimated to correlate with a 17% reduc-
tion in the risk of de novo stage 4 CKD.67 The integrity of 
the preserved parenchyma after partial nephrectomy is 
as predictive of risk of CKD as is the quantity. In a study 
that included 1,169 patients, each additional minute of 
warm ischaemia beyond 20 min during open or laparo-
scopic partial nephrectomy was associated with slightly 
greater renal impairment.68 The impact of warm ischae-
mia on the quantity and quality of preserved kidney was 
Table 3 | Risk factors associated with CKD after cancer nephrectomy
Risk factor De novo CKD Acceleration of  
pre-existing CKD
Nephron loss
Partial versus radical nephrectomy + ++
Demographics
Age + +
Gender ? ?
Ethnicity* ++ ++
Environmental factors
Smoking ? ?
Nutrition and diet (high intake of protein and salt) + ++
Genetic factors
APOL1 gene ++ ++
Other candidate genes ? ?
Comorbid conditions
Metabolic syndrome and obesity ++ ++
Diabetes mellitus +++ +++
Hypertension ++ +++
Cardiovascular diseases + +
Other comorbidities ? ?
Pre-existing renal factors
Microalbuminuria and proteinuria ++ ++
Haematuria ? ?
Low glomerular filtration rate ++ +++
Glomerular and interstitial diseases +++ +++
Pre-renal states and cardiorenal syndrome104 ? +
Obstructive conditions + +
History of acute kidney injury ++ +++
Kidney histopathology
Malignant tissue histopathology ? ?
Nonmalignant tissue histology ++ ++
Other factors
Perioperative events + +
Surgical technique +/– +/–
*Risk of de novo CKD or CKD progression after nephrectomy might be higher in black or Hispanic patients 
than in white patients.105 Abbreviations: CKD, chronic kidney disease; +, likely association; ++, highly likely 
association; +++, very highly likely association; +/–, unknown association; ?, questionable association.
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reflected by the decline in renal function immediately 
after the surgery. The degree of nadir eGFR reduction 
was associ ated with ultimate progression to CKD after 
adjusting for other risk factors.68 A warm ischaemic time 
>25 min was previously shown to more than double the 
risk of severe CKD.69 Interestingly, a study has shown that 
even if ischaemic time during partial nephrectomy is pro-
longed (>30 min) renal function outcomes are superior to 
those after radical nephrectomy.70
Thermal ablation techniques, including radio frequency 
ablation and cryoablation, are alternative minimally 
invasive nephron-sparing treatments for small renal 
lesions. These techniques, which can be performed 
using a percutaneous or laparoscopic approach, do not 
require dissec tion and clamping of the renal hilum and, 
therefore, confer minimal ischaemic insult.71 Although 
promising, the oncological and renal efficacy of thermal 
ablation in comparison with partial nephrectomy have yet 
to be established because of small sample sizes and lack 
of long-term follow-up data among existing studies.72–77 
Thermal ablation techniques and active surveillance (the 
most minimally invasive approach) are often reserved for 
patients who are elderly or comorbidly ill.78
Limitations of existing studies
Compelling evidence supports a protective benefit of 
partial versus radical nephrectomy in terms of develop-
ment of CKD. Preservation of kidney tissue in patients 
with RCC should, therefore, be a priority when possible. 
However, the majority of this evidence comes from single- 
centre cohort studies that lacked a standardized defini-
tion of renal impairment (measurements used included 
absolute serum creatinine levels, creatinine-based eGFR 
equations, and radioactive markers) and used various 
cutoff points of eGFR levels and stages of CKD stage as 
the primary outcomes. In addition to disparities between 
inclusion and exclusion criteria, large variability exists in 
duration of follow-up, which was as short as 3 months 
after surgery in some studies. The population-based 
studies had larger sample sizes and longer follow-up 
times. However, as the included data were obtained from 
cancer registries and the SEER database, the designations 
of CKD, cardiovascular events, and causes of deaths were 
extracted based on diagnostic or administrative codes 
and Medicare insurance claims. The results obtained 
depended largely on the accuracy of the coding and no 
actual measurements of renal function were available. In 
addition, as mentioned above, the EORTC trial is consid-
ered to be flawed because of premature closure and high 
crossover rates between the treatment groups.
ESRD is the definitive adverse renal outcome and is 
associ ated with significantly increased risks of cardio-
vascu lar morbidity and mortality. A 60-year old patient 
with ESRD is estimated to survive for only 4.6 years on 
dialysis compared with 21 years for an average person 
of the same age not on dialysis.79 Cardiovascular disease 
accounts for >50% of deaths in the ESRD population.80 
ESRD is, therefore, a significant public health burden. The 
Medicare expenditure for renal replacement therapy and 
its associated complications rose to nearly US$33 billion 
in 2010, nearly double compared with the previous 
decade.81 However, none of the studies mentioned 
above desig nated ESRD after nephrectomy as a primary 
end point. In a Canadian cohort of 1,151 patients with 
renal lesions undergoing nephrectomy, 2% of patients 
developed ESRD or required dialysis during a median 
follow-up of 32 months.34 Due to the low incidence, ESRD 
was examined only as part of a composite renal outcome. 
Similarly, in the MSKCC series, none of the participants 
needed acute or chronic renal replacement therapy.27 
In a SEER–Medicare linked cohort from 1988 to 2005, 
4% of patients who underwent radical nephrectomy and 
2% of patients who underwent partial  nephrectomy had 
developed ESRD at the end of 2008. However, the differ-
ence in risk of ESRD between the treatment groups failed 
to achieve statistical significance.36 In the subgroup analy-
sis of the EORTC trial, the incidences of ESRD in patients 
who underwent radical nephrectomy and in those who 
underwent partial nephrectomy were nearly identical 
(1.5% versus 1.6%).54 Controversy remains regarding the 
potential benefits of partial versus radical nephrectomy 
for small renal masses, especially the long-term survival 
benefits and ultimate renal outcome of ESRD—further 
research is needed.
Future research
Advanced CKD or ESRD and acquired cystic kidney 
disease (ACKD) are risk factors for RCC. An associ-
ation between RCC and ESRD with ACKD in patients 
on haemo dialysis was first reported in 1977.82 Compelling 
evidence has since confirmed that patients with ESRD 
have a higher risk of developing RCC than do the general 
population.83–87 Duration of dialysis has been associ-
ated with ACKD, which is an important risk factor for 
RCC.88–92 RCC might also develop in the native kidneys of 
renal transplant recipients, even in those who have good 
graft function.93–96 RCC that arise from the native kidneys 
of patients with ESRD or kidney transplant recipients are 
detected at a younger age, are of smaller size, are less likely 
to be symptomatic, and have less metastatic potential 
Risk factors for RCC and CKD
Kidney parenchyma pathology
■ Glomerular disease (diabetic nephropathy
 and/or glomerulosclerosis)
■ Arteriosclerosis
Systemic comorbidities
■ Diabetes mellitus
■ Hypertension
Risk factor for RCC
Acquired cystic disease in end-stage
renal disease
RCC CKD
Risk factors for CKD
Loss of functional kidney parenchyma
as a result of tumour growth
Risk factors associated with nephrectomy
■ Reduction in renal volume
■ Ischaemic time
Figure 2 | Potential bidirectional relationship between RCC and CKD. Intrinsic 
kidney pathology and systemic comorbidities are shared risk factors that can 
predispose toward both RCC and CKD. Acquired cystic disease in non-functioning 
kidneys in end-stage renal disease can lead to RCC. Conversely, tumour expansion 
and surgery-related risk factors in the setting of RCC can lead to CKD. 
Abbreviations: CKD, chronic kidney disease; RCC, renal cell carcinoma.
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than sporadic RCCs.97 They also had a wide spectrum 
of distinct pathologic features and prevalence that varies 
by dialysis vintage, with ACKD-associated RCC being 
most common in patients who have been on dialysis 
for ≥10 years.98 However, the exact pathophysiology by 
which the uraemic state, dialysis, and transplantation can 
cause malignant transformation in the kidney remains 
unknown and is likely multifactor ial.99 Future research 
should be extended to examine the long-term impact of 
nephrectomy on the development of ESRD as a primary 
end point, and the potential bidirectional (Figure 2) and 
causal relationships (Figure 3) between RCC and CKD. 
The use of population-based dialysis databases with long 
follow-up durations, frequent patient visits and evalu-
ations, and longitudinal measures of renal and cardio-
vascular outcomes and their associated risk factors might 
provide a unique opportunity to answer these questions 
by comparing patients with ESRD and RCC to  carefully 
matched patients who have ESRD without RCC.
More research is also needed to improve understanding 
of the pathophysiology of risk of CKD after nephrectomy 
and to quantify the perioperative risks and long-term 
benefits of nephron-sparing surgery and the role of other 
factors, such as pre-existing comorbidities and paren-
chymal renal diseases, in preventing new-onset CKD or 
slowing the rate of progression of pre-existing CKD. The 
development and validation of a prediction model (incor-
porating demographic and environmental factors, blood 
and urine indices, imaging studies, and histopathologic 
changes in malignant and nonmalignant tissue) to iden-
tify patients who are at risk of increased short-term and 
long-term oncological and non-oncological morbidity 
and mortality after nephrectomy is urgently needed. Such 
a model would help guide follow-up care after surgery 
or trigger discussion of alternative management options 
such as active surveillance or laparoscopic ablation.
Conclusions
Given the oncological equivalence of partial versus 
radical nephrectomy for stage I RCC, the current 
emphasis of clinical management has shifted to pre-
serving renal parenchyma to prevent development of 
post operative CKD and its associated morbidity and 
mortality. However, despite strong evidence support-
ing partial nephrectomy as the standard of care for T1a 
RCC and a viable option for T1b tumours, this approach 
has been underutilized, with reported rates of <50% in 
the USA in 2006100 and only 4% in England in 2002.101 
Its use is highly clustered around experienced tertiary 
care centres, and partial nephrectomy is most likely to 
be offered to young male patients with small tumours.100
Despite advances in surgical techniques, partial 
nephrectomy remains a challenging operation and is 
associated with a higher rate of adverse outcomes than 
is radical nephrectomy.102 A complication risk of ≥20% 
has been reported for partial nephrectomy of renal 
masses of moderate and high complexity.102,103 In addi-
tion, ongoing controversy and debate exists regarding the 
long-term cardio vascular and survival benefits of partial 
nephrectomy as a result of the inherent selection bias in 
retrospective observational studies and the lack of data 
from prospective clinical trials. Indeed, results from the 
only existing randomized trial, which had many limita-
tions, increased the controversy. The decision whether or 
not to recommend nephron-sparing surgery for patients 
with small renal masses should, therefore, be made on an 
individual basis after thorough evaluation of comorbid-
ities and risk factors, in particular the existence of base-
line renal insufficiency. The surgery must also be carefully 
planned to include estimates of parenchymal volume 
reduction and to minimize intraoperative ischaemic 
time. Given the substantial burden of CKD and ESRD, 
a great need exists for research on de novo and acceler-
ated CKD and ESRD after nephrectomy, and the bi- 
directional relation ship between RCC and CKD to prevent 
 progression to these ultimate adverse renal outcomes.
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Figure 3 | Hypothetical causal models for the association between cancer 
nephrectomy for RCC and increased risk of CKD. a | Factors that increase the risk 
of kidney injury are associated with both CKD and RCC but these outcomes are 
unrelated. b | Factors that increase the risk of kidney injury are associated with the 
development of CKD, which in turn increases the risk of RCC. c | Factors that 
increase the risk of kidney injury are associated with the development of RCC, 
which in turn increases the risk of CKD. Abbreviations: CKD, chronic kidney 
disease; RCC, renal cell carcinoma.
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